The key finding
Goreisan, a traditional Japanese herbal medicine made from five plant-based ingredients, did not significantly reduce the likelihood of needing surgery in patients with minimally symptomatic chronic subdural hematoma (CSDH). In comparative studies pooling 158 patients, 28% of those who took Goreisan eventually required surgery, versus 37% in control groups—a difference that was not statistically significant. The finding contrasts with earlier research showing Goreisan reduced recurrence rates after surgical treatment of CSDH, suggesting the herb may work differently in postsurgical versus nonoperative contexts.
What the study looked like
Researchers conducted a systematic review and meta-analysis following PRISMA guidelines, searching five major databases from inception through August 2025. They identified seven studies involving 356 total patients: 241 who received Goreisan and 115 who did not. Two of the studies directly compared Goreisan to no treatment, while five were single-arm observational studies tracking only Goreisan recipients. All patients had minimally symptomatic CSDH—a gradual accumulation of blood between the brain and skull that causes mild or no symptoms. Participants took 7.5 grams per day of Goreisan for one to twelve months. The primary outcome measured was whether patients eventually required surgical intervention to drain the hematoma. Researchers assessed study variability using the I² statistic to gauge heterogeneity across findings.
Why researchers think this happened
The authors note that Goreisan has shown benefit in preventing recurrence after CSDH surgery in a prior meta-analysis, but the mechanism may not translate to preventing progression in untreated cases. The herbal formula is thought to work by promoting fluid redistribution and reducing inflammation, which could help stabilize already-drained hematomas but may be insufficient to shrink existing blood collections that have not been surgically addressed. The observed heterogeneity (I² = 63% in comparative studies) suggests treatment response may vary by patient characteristics, hematoma size, or symptom severity—factors not uniformly reported across the included studies. The researchers acknowledge that the small number of comparative trials and variability in follow-up duration limit confidence in drawing firm conclusions about efficacy.
How to read this carefully
This meta-analysis included only seven studies, with just two directly comparing Goreisan to no treatment, limiting statistical power to detect a true effect. The studies were observational rather than randomized controlled trials, raising the possibility of selection bias—patients who received Goreisan may have differed in baseline hematoma size or symptom severity from those who did not. Moderate heterogeneity in the comparative studies suggests results varied across settings, and the analysis could not determine whether specific subgroups (such as those with smaller hematomas) might benefit. The five single-arm studies showed a 15% surgery rate, but without a control group, it is impossible to know whether this reflects Goreisan’s effect or simply the natural course of mild CSDH, many of which resolve without intervention.
What this means for everyday life
For individuals diagnosed with a small, minimally symptomatic chronic subdural hematoma, this analysis suggests Goreisan should not be relied upon as a proven strategy to avoid surgery. While the herbal medicine appears safe and may still play a role after surgical drainage, its benefit in the nonoperative setting remains uncertain. Patients managing mild CSDH through watchful waiting may want to discuss with their neurologist whether any interventions—herbal or otherwise—are supported by evidence, rather than assuming traditional remedies offer clear protection. Given the lack of high-quality randomized trials, decisions about Goreisan use should weigh personal preferences alongside the understanding that robust proof of benefit is currently lacking.